New naphthalene-linked pyrazoline-thiazole hybrids as prominent antilung and antibreast cancer inhibitors


Ciftci H., Otsuka M., Fujita M., Sever B.

TURKISH JOURNAL OF CHEMISTRY, cilt.48, sa.6, ss.856-866, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 48 Sayı: 6
  • Basım Tarihi: 2024
  • Doi Numarası: 10.55730/1300-0527.3704
  • Dergi Adı: TURKISH JOURNAL OF CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Chemical Abstracts Core, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.856-866
  • Anadolu Üniversitesi Adresli: Evet

Özet

The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), pioneer members of the receptor tyrosine kinase subfamily, are frequently mutated and/or overexpressed in several types of human cancers, including nonsmall cell lung cancer (NSCLC) and breast cancer, which are leading causes of cancer-related deaths worldwide. EGFR and HER2-focused anti-NSCLC and antibreast cancer studies encouraged us to search for new potential agents. For this purpose, in the current work, naphthalene-linked pyrazoline-thiazole hybrids ( BTT-1 - 10 and BTP-1-10) were synthesized and examined for their antiproliferative effects on A549 NSCLC and MCF-7 breast cancer cell lines. According to the results, the MTT assay showed that BTT-5 induced strong toxicity in A549 cells with an IC50 value of 9.51 +/- 3.35 mu M compared to lapatinib (IC50 = 16.44 +/- 3.92 mu M). BTT-5 also presented a high selectivity profile between the Jurkat cell line and PBMCs (healthy) (SI = 65.65). Furthermore, BTT-5 augmented apoptosis significantly in A549 cells (18.40%). BTT-5 displayed significant EGFR inhibition (58.32%) and no significant HER2 inhibition at 10 mu M concentration, showing its selective kinase inhibitory effects. The molecular docking assessment indicated that BTT-5 showed high affinity with a different binding profile than lapatinib in the ATP binding cleft of EGFR. Consequently, BTT-5 can serve as a lead for future anti-NSCLC studies.